Skip to main content
Fig. 8 | Molecular Cancer

Fig. 8

From: Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer

Fig. 8

In vitro and in vivo validation of targeting the CXCR4/CXCL12 axis to inhibit angiogenesis. A Quantitative RT-PCR analyses of CXCR4 and CXCL12 mRNA expression in prostate NEC and TEC (mean +—SEM; n = 3, p < 0.001). B EZ4U cell prolifaration assay with NEC and TEC treated with 10 µM AMD3100 for 24 h (mean +—SEM; n = 3, p < 0.05). C Micrographs (left) and quantification of wound closure (right) of NEC and TEC migration in scratch wound assay. Cells were treated with 10 µM AMD3100 for 24 h (mean +—SEM; n = 3, *p < 0.05, **p < 0.01). D Micrographs showing immunohistochemistry results after probing for the endothelial marker CD31 in tissues treated, or not, with the CXCR4 inhibitor AMD3100. E Quantification of intratumoral and peritumoral microvessel density in control vs AMD3100 treated murine PCa tissue

Back to article page

Molecular Cancer

ISSN: 1476-4598